Does Cortisone Acetate Interact with Somapacitan Beco?
CDI records a moderate classification for Cortisone Acetate and Somapacitan Beco. The stored summary is: SOGROYA may inhibit 11βHSD-1 and reduce serum cortisol concentrations, potentially requiring increased glucocorticoid maintenance or stress doses. The mechanism involves gh inhibits 11βhsd-1, reducing conversion of cortisone to active cortisol. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
GH inhibits 11βHSD-1, reducing conversion of cortisone to active cortisol
What To Tell Your Doctor or Pharmacist
If you are taking Cortisone Acetate and your doctor is considering prescribing Somapacitan Beco (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider